Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/26/2025

Concurrent Use of Meloxicam and Prednisone

Risks of Concurrent Use

  • The combination of meloxicam and prednisone significantly increases the risk of gastrointestinal adverse events, including ulceration and bleeding, according to the Society for Immunotherapy of Cancer (SITC) guidelines 1
  • Both medications independently can cause gastrointestinal irritation, and their combination has a synergistic effect on increasing this risk 1
  • The Society for Immunotherapy of Cancer (SITC) guidelines recommend that patients receiving corticosteroids should also be on proton pump inhibitor therapy for GI prophylaxis 1

Clinical Considerations

  • In inflammatory arthritis, if NSAIDs alone are ineffective, prednisone may be added, but this should be done with caution and appropriate protective measures 1
  • For patients with polymyalgia rheumatica, guidelines strongly recommend using glucocorticoids instead of NSAIDs, indicating these medications should generally not be used together 2

Risk Mitigation Strategies

  • Add proton pump inhibitor therapy for GI prophylaxis when using both medications concurrently 1
  • Consider calcium and vitamin D supplementation with prolonged steroid use to prevent bone density loss 1
  • Use the lowest effective dose of both medications for the shortest possible duration 2

Alternative Approaches

  • For inflammatory conditions requiring both anti-inflammatory and pain management, consider using prednisone alone at appropriate doses, as it has both anti-inflammatory and analgesic effects 2
  • If prednisone alone is insufficient, consider alternative pain management strategies that don't increase GI risk 1
  • In some cases, disease-modifying agents may be more appropriate than combination therapy with NSAIDs and corticosteroids 1, 2

Transitioning from Prednisone to Meloxicam

Gastrointestinal Protection Strategy

  • The Society for Immunotherapy of Cancer guidelines recommend PPI prophylaxis for patients receiving corticosteroids, and this protection should extend through any NSAID use that follows, including meloxicam, to manage the significantly increased risk of gastrointestinal adverse events 3
  • Patients who were on prednisone for more than 3 weeks at doses >30 mg daily (or equivalent) should continue PPI therapy and monitor for signs of adrenal insufficiency during the first few weeks after starting meloxicam, as their body adjusts to being off corticosteroids 3